Long-term outcomes (beyond 5 years) of liver transplant recipients-A transatlantic multicenter study.

Autor:	Palaniyappan N; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, UK.; Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, UK., Peach E; Lifespan and Population Health, School of Medicine, University of Nottingham, UK., Pearce F; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, UK.; Lifespan and Population Health, School of Medicine, University of Nottingham, UK., Dhaliwal A; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Campos-Varela I; Liver Unit, Department of Medicine, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Cant MR; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Dopazo C; Department of Hepatobiliopancreatic Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain., Trotter J; Baylor University Medical Center, Dallas, Texas, USA., Divani-Patel S; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Hatta AAZ; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Hopkins L; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Testa G; Baylor University Medical Center, Dallas, Texas, USA., Bilbao A; Department of Hepatobiliopancreatic Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain., Kasmani Z; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Faloon S; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Mirza DF; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK.; Centre for Liver and Gastrointestinal Research, NIHR Birmingham Biomedical Research, University of Birmingham, Birmingham, UK., Klintmalm GB; Baylor University Medical Center, Dallas, Texas, USA., Bilbao I; Department of Hepatobiliopancreatic Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain., Asrani SK; Baylor University Medical Center, Dallas, Texas, USA., Rajoriya N; The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK.; Institute of Immunology & Immunotherapy, University of Birmingham, UK., Aravinthan AD; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, UK.; Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, UK.
Jazyk:	angličtina
Zdroj:	Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [Liver Transpl] 2024 Feb 01; Vol. 30 (2), pp. 170-181. Date of Electronic Publication: 2023 Aug 18.
DOI:	10.1097/LVT.0000000000000244
Abstrakt:	The long-term (>5 y) outcomes following liver transplantation (LT) have not been extensively reported. The aim was to evaluate outcomes of LT recipients who have survived the first 5 years. A multicenter retrospective analysis of prospectively collected data from 3 high volume LT centers (Dallas-USA, Birmingham-UK, and Barcelona-Spain) was undertaken. All adult patients, who underwent LT since the inception of the program to December 31, 2010, and survived at least 5 years since their LT were included. Patient survival was the primary outcome. A total of 3682 patients who survived at least 5 years following LT (long-term survivors) were included. Overall, median age at LT was 52 years (IQR 44-58); 53.1% were males; and 84.6% were Caucasians. A total of 49.4% (n=1820) died during a follow-up period of 36,828 person-years (mean follow-up 10 y). A total of 80.2% (n=1460) of all deaths were premature deaths. Age-standardized all-cause mortality as compared to general population was 3 times higher for males and 5 times higher for females. On adjusted analysis, besides older recipients and older donors, predictors of long-term mortality were malignancy, cardiovascular disease, and dialysis. Implementation of strategies such as noninvasive cancer screening, minimizing immunosuppression, and intensive primary/secondary cardiovascular prevention could further improve survival. (Copyright © 2023 American Association for the Study of Liver Diseases.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu